Press & Media
Stay up to date on regulatory news with ILCN, including @FDAOncology approvals of two combinations for #NSCLC treatment: #LCSMRead More
MET exon 14 skipping mutations occur in 3-4% of patients w/#NSCLC, typically in the absence of other driver mutations. Host @NarjustFlorezMD discusses the unique clinical issues surrounding MET exon with Dr. Ross Camidge & @NReguart. Listen Now: #LCSM https://t.co/9cwke7ynJ4Read More
We welcome media to attend the IASLC 2023 Latin America Conference on Lung Cancer (LALCA23). Further information and details about media policies and embargoes can be found below.
For questions, please contact:
VP Public Relations, David James Group
Phone: +1 630 670 2745
Associate Director, Marketing and Communications
Failure to comply with these policies may result in the immediate revocation of any privileges of the current LALCA and for future IASLC events. The IASLC reserves the right to change these policies when needed without notice.